Since CCSC-enriched CD133+CD44+ cells are more resistant to conventional therapies than the other differentiated tumor cells, and based on our previous results that PRDX2 is essential for maintaining the colon cancer stem cell-like phenotype [40], the significance of PRDX2 in CD133+CD44+ CCSCs was investigated in the present study. The gene discussed is PRDX2; the disease is colonic neoplasm.